NextCell Pharma AB (FRA:65G)

Market Cap	12.93M -39.0%
Revenue (ttm)	908.65K +4.1%
Net Income	-3.58M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	475
Open	0.1040
Previous Close	0.1048
Day's Range	0.1040 - 0.1040
52-Week Range	0.0462 - 0.2760
Beta	n/a
RSI	46.47
Earnings Date	May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 65G

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.

Financial numbers in SEK